Every fact traced to its source, and checked against it. We track the entities shaping AI — verify a claim, or open a knowledge file.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
A wave of governance changes is under way across sectors. Activists and large holders are settling for board seats and cooperation agreements (Fivespan at Stride, Al Shams), companies are formalizing oversight through new bodies like Stride's Capital Allocation Committee, and CEO succession is being carried out in an orderly way (Keyser to advisor, Deputy CEO promotions, Co-CEO and CEO handoffs at Mattel, Brown-Forman, BellRing and Arcutis). Corporate restructurings, including Chevron's Hess Midstream divestiture reviewed by an independent conflicts committee, and NGEx's spin-out vote add to the picture. The tone is collaborative and stabilizing rather than adversarial.
Sell-side analysts are turning selective heading into the Nov. 3 midterms and the fiscal 2027 budget talks. J.P. Morgan's Seth Seifman downgraded Leidos to Neutral and cut its target, kept Boeing and StandardAero at Overweight, and called aerospace and defense sentiment sour even though the broader market is near highs. Elsewhere, ratings diverged by company. Buys went to quantum computing (D-Wave), small modular reactors (NuScale), fuel-cell power (Bloom Energy) and biotech (Iovance, ivonescimab), while Wendy's drew a neutral initiation after its take-private plan was abandoned and Capital One was framed as a K-shaped-economy credit story.
Finance chiefs are changing at several companies (Rivian's CFO leaving for GE Vernova, PJT Partners, Penguin Solutions) while the role is being reshaped by AI. Examples are PwC and SAP extending their AI collaboration, SAP's 'Autonomous Enterprise', Harvey acquiring Guardrails AI, and Morgan Foods' CFO describing a move to agentic adoption. Regional banks such as Origin Bancorp and the bank whose CFO is Donald Hinson report improving net interest margin (3.99%) and merger synergies on track, but face deposit competition and the Durbin Amendment from mid-2027. Companies are using productivity programs (NIKE's Pace model, $530M in cost savings) and balance-sheet moves (a planned credit facility redraw to repay convertible debentures, buybacks) to offset these pressures.
Oncology is advancing on three fronts at once. Late-stage bispecific, ADC and personalized mRNA vaccine programs are reaching regulatory and data milestones: the ivonescimab PDUFA date of 2026-11-14, intismeran data at ESMO, and EXCALIBER-RRMM Phase 3 PFS results. AstraZeneca is positioning AI-designed, robotically tested biologics as the future of discovery. McKesson and CD&R's Option Care deal and behavioral-health tie-ins with oncology practices point to consolidation and a broader care model. Unrelated items in the feed (rockets, dinosaurs, data-center politics) don't belong to the story.
Biotech is in a milestone-driven phase. Eli Lilly's GLP-1 demand, BioArctic's Leqembi royalties, and IND filings and FDA end-of-phase meetings at Prelude, Ernexa, MapLight and Galectin are all pushing programs toward clinical and regulatory decision points. Leadership changes at Idorsia, Everest and MindWalk, plus VivoSim's projected 500%+ revenue growth and up to $45M in Lilly milestones, show capital and talent moving toward translational and platform-based models. The AI-bio overlap is growing through OpenAI Foundation funding and AI-driven discovery. Washington's self-regulation approach and an AI czar appointment sit uneasily beside the Kimi bioweapon-jailbreak finding, which shows how weak AI biosecurity safeguards are.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHarness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board
“Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in Huntington’s disease Clinical Advisory Bo…”
Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers
“Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers US stocks wavered Tuesday in volatile trading as Wall Street continued assessing the AI jitters that have hammered markets in recent weeks…”
Stock market today: Dow, S&P 500, Nasdaq edge higher in volatile trading as Wall Street assesses AI fears
“Stock market today: Dow, S&P 500, Nasdaq edge higher in volatile trading as Wall Street assesses AI fears US stocks edged higher Tuesday in volatile trading as Wall Street continued assessing the AI jitters that have hammered markets in recent weeks…”
Buildings Construction Industry Report 2025-2033: Expansion Driven by Sustainability in North America and Europe, Infrastructure Expansion in Asia-Pacific and Mega-Projects in the Middle East
“Buildings Construction Industry Report 2025-2033: Expansion Driven by Sustainability in North America and Europe, Infrastructure Expansion in Asia-Pacific and Mega-Projects in the Middle East Dublin, Feb…”
Marketing Technology (MarTech) Market Worth USD 3.28 Trillion by 2035 Driven by AI, Agile Marketing, and Privacy-First Personalization
“Marketing Technology (MarTech) Market Worth USD 3.28 Trillion by 2035 Driven by AI, Agile Marketing, and Privacy-First Personalization Ottawa, Feb…”
Video Friday: Autonomous Robots Learn By Doing in This Factory
“IEEE Spectrum - Technical Title: Video Friday: Autonomous Robots Learn By Doing in This Factory Date: 2026-02-06 17:00 Source: https://spectrum.ieee.org/autonomous-warehouse-robots <img src="https://spectrum.ieee.org/media-library/robotic-arms-on-mobile-bases-sort-crates-on-a-conveyor-belt-in-a-warehouse.png?id=6390782…”
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts measure the same attribute (cash) for the same entity (Tesla Inc.) at the same point in time (2025-12-31). Although labeled with different fiscal period categories (FY 2025 vs Q4 2025), both periods end on the same date, making them equivalent time snapshots. The values differ drastically: $16.513 billion vs $44.06 USD. Since Q4 2025 is the final quarter of FY 2025, both should report identical cash balances at period-end. A 375 million-fold magnitude difference indicates a real contradiction, likely caused by a data quality issue (unit error, miscategorization, or source error in FACT B).
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Every fact is traceable to the document it came from — see how we source every claim.
AstraZeneca's scientist argues that proprietary data, robots and AI will design the next biologics, but the article carrying her case scored 0% on our claim check. The only AI-adjacent oncology company with audited numbers here is Summit, whose FY2025 loss was $1.08 billion.
AI demand is straining chip supply. SEC-filed figures show Micron's capital spending more than doubled in two years and its cash rose sharply. Deals and research are pushing toward new silicon. Several sources behind these stories score poorly on our reliability checks, and we flag where.
A survey reported by MIT Technology Review says every respondent plans to use agentic AI within two years, yet the money is flowing to governance, security and data plumbing. We flag that the survey's source scored 0% on our claim checks, and we ground the compute story in SEC-checked Nvidia figures.
A cluster of CEO handoffs runs from July to early October 2026. Almost none of it concerns AI. The one technology-adjacent filing, Kneat's, warns of vendors building rival validation tools. Source reliability scores of 30% and 57% suggest treating the glowing language with care.
Meta is building an enterprise platform under a departing MongoDB chief, and startup capital is flowing to narrow, vertical AI agents. Practitioners warn that policy must be enforced by the system, not the model, and that AI is poor at calculation. Every claim here traces to a named source, and we flag where those sources are weaker.
A survey says 100% of enterprises expect to use agentic AI within two years, yet only about 45% of company data is AI-accessible. We set that against Nvidia's checked SEC figures and CB Insights startup interviews. The survey source has a poor verification record, so we flag it.
Oncology's AI story rests on two tracks: personalized mRNA vaccines nearing detailed data, and AI-designed biologics at AstraZeneca. The AI claims are mostly aspirational and come from a source that scored 0% on our fidelity checks. The clinical and commercial signals are better sourced.
A survey says every enterprise respondent plans to use AI agents within two years, yet agents reach only about 45% of company data. Our check of the source found none of its 11 tested claims held up, so we treat the figures as unconfirmed. Governance-led partnerships and Nvidia's verified SEC figures show where spending is going.
SEC-filed figures show Micron's capital spending roughly doubled in fiscal 2025 and its cash pile reached $25.0B in fiscal Q3 2026. Around that hard data sit analyst claims of far weaker quality, and we flag which is which. The dossier holds no model or agent data, so this is a hardware-and-power story.
Banks, insurers and software vendors are committing to AI agents, and every respondent in one survey plans to use them within two years. The same survey says access to company data is the weak point. That source failed our reliability check, so we flag it.
Google now lets users remove visible watermarks from Gemini-made images, video and music — even as OpenAI loses another senior executive and AI infrastructure spending keeps compounding. Enterprise AI adoption data and a live model-compression benchmark show where the real, verifiable action is.
Nvidia's $950B Korea agreement, an AMD-Cerebras inference tie-up, and a GlobalFoundries silicon-photonics deal with Washington all landed in July 2026 even as the SOXX index fell 25% and leveraged chip ETFs dropped 62% from highs. Via News traces the buildout deal by deal against the sell-off.
Nvidia secured long-term memory supply from SK hynix and GlobalFoundries landed a $300M federal photonics award, yet AI-chip stocks sold off sharply in late July. Via News traces the gap between strengthening technical/supply fundamentals and a market repricing execution risk at Apple, Vicor and Amkor.
Survey data cited by MIT Technology Review says every enterprise respondent plans to deploy agentic AI within two years, yet agents can see under half of company data on average. Platform vendors are answering with governance layers; a new venture-backed cohort is answering by avoiding the data problem entirely.
Brad Lightcap, OpenAI's special projects lead and the company's former chief operating officer, has announced his departure from the company.
Manulife expanded its Microsoft partnership to embed AI agents across global operations, while Box rolled out new admin controls for enterprise AI agent access. Fintech dispute-resolution startup Casap and Snowflake's new CoCo control plane show the same rush to operationalize agentic AI ahead of governance frameworks.
The SOXX semiconductor index has fallen 25% from its highs, with leveraged chip ETFs down 62%, even as AI infrastructure deal-making continues. GlobalFoundries struck a CHIPS Act partnership with the Commerce Department, AMD partnered with Cerebras, and Nvidia and SK hynix signed new AI accelerator supply agreements.
Micron and SanDisk are among 2026's top-performing chip stocks on AI memory demand, but both have fallen sharply from June record highs. Figures dated and sourced.
Semiconductor fundamentals are pulling away from Wall Street sentiment: Amkor Technology reported record earnings and SK hynix secured new AI-memory supply agreements even as leveraged AI-infrastructure ETFs fell sharply from highs. GlobalFoundries picked up a $300 million CHIPS Act award plus a government equity stake, while Skyworks and Qorvo named joint leadership ahead of their merger and Kalray struck an AI-networking partnership with Bull.
Amkor Technology reported record results on surging AI server packaging demand, even as semiconductor stocks fell sharply in late July 2026. GlobalFoundries, Kalray, and Skyworks-Qorvo are each expanding capacity or partnerships to meet data center and AI infrastructure needs.
Jeff Dean, Sanjay Ghemawat and two other senior Google researchers left within a single week to found rival startup Discovery Loop, while Demis Hassabis stepped back from day-to-day DeepMind leadership. Alphabet shares fell, even as the company chose to invest in the new venture rather than treat the exits as a pure loss.
Oriol Vinyals, co-lead of Google's Gemini models, is departing to co-found a new venture called Discovery Loop. The move puts him in direct competition with his former employer in the capital-intensive frontier-AI market, facing the same fundraising, compute, and talent hurdles every new AI lab confronts.
Bloom Energy struck a $1.7 billion fuel-cell agreement with Nebius AI and a separate strategic deal with utility AEP, both aimed at powering AI data centers directly rather than waiting on grid upgrades. The company also expanded its South Korea distribution through SK Ecoplant and SK Eternix and continues supplying Oracle, pointing to fuel cells as a load-bearing part of AI infrastructure scaling.
The SOXX semiconductor index fell roughly 25% in late July 2026, with leveraged chip ETFs down 62% from highs, even as Amkor posted better-than-expected results and SK hynix signed long-term AI-memory deals. Washington backed GlobalFoundries with a $300 million CHIPS award and a 1% equity stake, while Skyworks and Qorvo finalized merger leadership — consolidating suppliers just as AI infrastructure demand keeps climbing.
A cluster of AI-native biotech platforms launched in rapid succession in early-to-mid 2026, built on NVIDIA GPU infrastructure now supplied to Thermo Fisher and Eli Lilly. MindWalk debuted its ReefIQ platform, built atop a 660-million-pattern biological database called HYFT, while Novo Nordisk shut its internal cell therapy unit to license the work to AI-native platform Cellular Intelligence.
KLA raised its September-quarter revenue guidance to $4 billion and lifted its 2026 wafer fab equipment market outlook to the low-$150 billion range. The company also raised its advanced packaging revenue target to $1.1 billion and announced a 10-for-1 stock split, pointing to sustained AI chip and HBM memory production growth.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.